Skip to main content
Erschienen in: Clinical Rheumatology 5/2005

01.10.2005 | Original Article

Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study

verfasst von: Canan Tikiz, Hakan Tikiz, Fatma Taneli, Gül Gümüşer, Çiğdem Tüzün

Erschienen in: Clinical Rheumatology | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Observational studies suggest that statin use may be associated with lower incidence of fracture. However, there are conflicting data for their effects on bone remodeling parameters and bone mineral density (BMD). In the present study, we aimed to investigate the effects of simvastatin on bone metabolism and BMD in subjects with hypercholesterolemia (>240 mg/dl). For this purpose, 32 postmenopausal osteopenic subjects who were given simvastatin treatment (20 mg/day) and not on osteoporosis treatment were included in the study. During the 1-year follow-up period, the total cholesterol level decreased from 262.1±30.9 to 202.2±30.1 mg/dl (p<0.0001). At a period as early as the 3rd month, levels of the anabolic markers, e.g., bone-specific alkaline phosphatase (BSAP) and osteocalcin (OCL), were found to be significantly increased (from 120.8±56.6 to 149.5±57.6 IU/l, p=0.008, and from 20.8±12.6 to 34.7±18.4 μg/l, p=0.015, respectively) while no significant change was observed in the resorptive marker of serum N-telopeptide of type I collagen (CTX). At the 6th and 12th month, BSAP and OCL were both found to be decreased below the pretreatment values. While a significant reduction was found in BSAP levels (from 120.8±56.6 to 55.9±18.8 IU/l, p<0.001), no significant change was observed in CTX levels after the 6-month treatment period. Parathyroid hormone showed a gradual profound increase during the follow-up period (from 62.7±41.5 to 108.4±51.7 pg/ml, p<0.001). No significant change was found in BMD levels at the spine, femoral neck, Ward’s triangle, and trochanter at the end of the 1-year follow-up period. In conclusion, simvastatin treatment showed a short-lasting anabolic effect on bone metabolism. However, this effect was lost by prolongation of therapy. The decrease in both anabolic and resorptive markers at the 6th and 12th month suggests that simvastatin affects bone metabolism mostly in favor of inhibition of the bone turnover in a long-term observation period although this inhibitory effect was not reflected in BMD.
Literatur
1.
Zurück zum Zitat Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712–1719 Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712–1719
2.
Zurück zum Zitat Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949CrossRefPubMed Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949CrossRefPubMed
3.
Zurück zum Zitat Massy ZA, Keane WF, Kasiske BL (1996) Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction. Lancet 347:102–103 Massy ZA, Keane WF, Kasiske BL (1996) Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction. Lancet 347:102–103
4.
Zurück zum Zitat Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 357:509–512CrossRefPubMed Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 357:509–512CrossRefPubMed
5.
Zurück zum Zitat van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850–1855CrossRefPubMed van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850–1855CrossRefPubMed
6.
Zurück zum Zitat Lacroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, Mcneeley G, Passaro MD, Jackson RD (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med 139:97–104PubMed Lacroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, Mcneeley G, Passaro MD, Jackson RD (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med 139:97–104PubMed
7.
Zurück zum Zitat Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216CrossRefPubMed Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216CrossRefPubMed
8.
Zurück zum Zitat Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188CrossRefPubMed Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188CrossRefPubMed
9.
Zurück zum Zitat Pasco J, Kotowicz M, Henry M, Sanders K, Nicholson G (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537–540CrossRefPubMed Pasco J, Kotowicz M, Henry M, Sanders K, Nicholson G (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537–540CrossRefPubMed
10.
Zurück zum Zitat Bauer D, Mundy G, Jamal S, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and fracture: results of four prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146–152CrossRefPubMed Bauer D, Mundy G, Jamal S, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and fracture: results of four prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146–152CrossRefPubMed
11.
Zurück zum Zitat Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210CrossRefPubMed Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210CrossRefPubMed
12.
Zurück zum Zitat Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218–2219CrossRefPubMed Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218–2219CrossRefPubMed
13.
Zurück zum Zitat Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865CrossRef Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865CrossRef
14.
Zurück zum Zitat Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380–384 Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380–384
15.
Zurück zum Zitat Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537–554CrossRefPubMed Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537–554CrossRefPubMed
16.
Zurück zum Zitat Cauley J, Jackson R, Pettinger M (2000) Statin use and bone mineral density (BMD) in older women: the Women’s Health Initiative Observational Study (WHI-OS). J Bone Miner Res 15 [Suppl 1]:1068 Cauley J, Jackson R, Pettinger M (2000) Statin use and bone mineral density (BMD) in older women: the Women’s Health Initiative Observational Study (WHI-OS). J Bone Miner Res 15 [Suppl 1]:1068
17.
Zurück zum Zitat Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581–589CrossRefPubMed Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581–589CrossRefPubMed
18.
Zurück zum Zitat Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG CoA-reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137–1142 Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG CoA-reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137–1142
19.
Zurück zum Zitat Chan MH, Mak TW, Chiu RW, Chow C, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 86:4556–4559 Chan MH, Mak TW, Chiu RW, Chow C, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 86:4556–4559
20.
Zurück zum Zitat Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis 11:84–87PubMed Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis 11:84–87PubMed
21.
Zurück zum Zitat Mostaza JM, De la Piedra C, Curiel MD, Pena R, Lahoz C (2001) Pravastatin therapy increases procollagen I N-terminal propeptide. Clin Chim Acta 308:133–137CrossRefPubMed Mostaza JM, De la Piedra C, Curiel MD, Pena R, Lahoz C (2001) Pravastatin therapy increases procollagen I N-terminal propeptide. Clin Chim Acta 308:133–137CrossRefPubMed
22.
Zurück zum Zitat Staal A, Frith JC, French MH, Swartz J, Güngör T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG CoA-reductase activity. J Bone Miner Res 18:88–96PubMed Staal A, Frith JC, French MH, Swartz J, Güngör T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG CoA-reductase activity. J Bone Miner Res 18:88–96PubMed
23.
Zurück zum Zitat Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 14:273–282CrossRefPubMed Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 14:273–282CrossRefPubMed
24.
Zurück zum Zitat Nussbaum S, Potts JT (1994) Advances in immunoassays for parathyroid hormone. Clinical applications to skeletal disorders of bone and mineral metabolism. In: Bilezikian JP, Levine MA, Marcus R (eds) The parathyroids: basics and clinical concepts. Raven, New York, pp 157–169 Nussbaum S, Potts JT (1994) Advances in immunoassays for parathyroid hormone. Clinical applications to skeletal disorders of bone and mineral metabolism. In: Bilezikian JP, Levine MA, Marcus R (eds) The parathyroids: basics and clinical concepts. Raven, New York, pp 157–169
25.
Zurück zum Zitat World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva
26.
Zurück zum Zitat Maeda T, Matsunuma A, Kawane T, Horiuchi N (2000) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874–877 Maeda T, Matsunuma A, Kawane T, Horiuchi N (2000) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874–877
27.
Zurück zum Zitat Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/ differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424–444CrossRefPubMed Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/ differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424–444CrossRefPubMed
28.
Zurück zum Zitat Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584–587CrossRefPubMed Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584–587CrossRefPubMed
29.
Zurück zum Zitat Khosla S (2003) Parathyroid hormone plus alendronate. A combination that does not add up. N Engl J Med 349:1277–1279 Khosla S (2003) Parathyroid hormone plus alendronate. A combination that does not add up. N Engl J Med 349:1277–1279
30.
Zurück zum Zitat Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853PubMed Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853PubMed
31.
Zurück zum Zitat Hock JM, Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65–72 Hock JM, Gera I (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65–72
32.
Zurück zum Zitat Cummings S, Black D, Thompson D, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082CrossRefPubMed Cummings S, Black D, Thompson D, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082CrossRefPubMed
33.
Zurück zum Zitat McClung M, Geusens P, Miller P, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340CrossRefPubMed McClung M, Geusens P, Miller P, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340CrossRefPubMed
Metadaten
Titel
Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study
verfasst von
Canan Tikiz
Hakan Tikiz
Fatma Taneli
Gül Gümüşer
Çiğdem Tüzün
Publikationsdatum
01.10.2005
Erschienen in
Clinical Rheumatology / Ausgabe 5/2005
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-1053-x

Weitere Artikel der Ausgabe 5/2005

Clinical Rheumatology 5/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.